PSNL News and Press, Personalis Inc. From 02/03/23

Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, and Moderna, Inc. (Nasdaq: MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced the companies have signed a new agreement to continue using the Personalis Ne...

Summary ARK Invest’s 13F portfolio value decreased from $14.35B to $11.54B this quarter. They increased Tesla, Ginkgo Bioworks, and Coinbase Global stakes while decreasing NVIDIA, Fate Therapeutics, and TuSimple Holdings during the quarter. The top three positions are Exact S...

Summary Personalis is a small-cap cancer genomics company with a next-gen cancer diagnostics platform whose stock has lost over 80% of its value over the past twelve months. Personalis is reporting substantial losses, however, the company’s strong balance sheet could provide them...

Shares of Personalis ( NASDAQ: PSNL ) rose 10% after the bell on Wednesday after it forecasted fourth quarter revenue of about $16.7 million, and said it expects full-year revenue of $65 million, above its previously provided range of $63 million to $64 million. The Seeki...

Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, today reported unaudited preliminary revenue for the fourth quarter and full year ended December 31, 2022. Personalis estimates revenue of approximately $16.7 million for the fourth quarter of 2022 and appr...

Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, today announced that John West, co-founder, CEO and member of the board of directors of Personalis, notified the Company of his decision to retire as CEO and a director at the end of the calendar year. Mr. West...

Personalis, Inc. (Nasdaq: PSNL) today announced a collaboration with UC San Francisco (UCSF) that will deploy a personalized liquid biopsy-based research use only (RUO) assay for a study of patients with colorectal cancer. The research efforts will use Personalis’ NeXT Personal ™...

Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer, announced today that its management team will present at the 34 th Annual Piper Sandler Healthcare Conference on Wednesday, November 30, 2022 at 1:30 p.m. Eastern Time in New York, NY. About Per...

Personalis, Inc. (Nasdaq: PSNL) today announced that the company will share data resulting from expanded features of its NeXT Platform® at the Society for Immunotherapy of Cancer (SITC) Annual Meeting , November 8-12 in Boston, with three abstracts that highlight advanced R&...

Personalis, Inc. (PSNL) Q3 2022 Earnings Conference Call November 2, 2022 17:00 ET Company Participants Caroline Corner - Investor Relations John West - President and Chief Executive Officer Aaron Tachibana - Chief Financial Officer Conference Call Particip...